Last reviewed · How we verify
VAL-1221
At a glance
| Generic name | VAL-1221 |
|---|---|
| Sponsor | Parasail, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravenous VAL-1221 Lafora Expanded Access Protocol
- VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAL-1221 CI brief — competitive landscape report
- VAL-1221 updates RSS · CI watch RSS
- Parasail, LLC portfolio CI